Search

Your search keyword '"Brent A. Neuschwander-Tetri"' showing total 190 results

Search Constraints

Start Over You searched for: Author "Brent A. Neuschwander-Tetri" Remove constraint Author: "Brent A. Neuschwander-Tetri" Topic medicine Remove constraint Topic: medicine
190 results on '"Brent A. Neuschwander-Tetri"'

Search Results

1. Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms

2. NAFLD: Reporting Histologic Findings in Clinical Practice

Catalog

Books, media, physical & digital resources

3. Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET‐NASH Study

4. The Importance of Glycemic Equipoise in NASH

6. Inappropriate Testing for Acute Viral Hepatitis Is Common—Impact of an Intervention Using the Electronic Health Record in a Tertiary Teaching Hospital in the United States

7. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease

8. Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH)

9. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study

10. The molecular basis for current targets of NASH therapies

11. Correlates, Trends, and Short-Term Outcomes of Venous Thromboembolism in Hospitalized Patients with Hepatocellular Carcinoma

12. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials

13. S2679 An Unusual Suspect for Cholestatic Liver Injury

14. A trans-ancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation

15. TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial

16. The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis

17. 1472-P: Clinical Profile of Nonalcoholic Fatty Liver Disease in Adults with Type 2 Diabetes Mellitus

18. Opioid Use Is More Common in Nonalcoholic Fatty Liver Disease Patients with Cirrhosis, Higher BMI, and Psychiatric Disease

19. An Inhibitor of Arginine‐Glycine‐Aspartate‐Binding Integrins Reverses Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis

20. Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study

21. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

22. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis

23. Mechanisms of NAFLD development and therapeutic strategies

24. Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science

26. Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis

28. Performance characteristics of vibration‐controlled transient elastography for evaluation of nonalcoholic fatty liver disease

29. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study

30. New insights into the role of Lith genes in the formation of cholesterol-supersaturated bile

31. An Unusual Case of Cholestatic Hepatitis

33. Impact of Obeticholic Acid on the Lipoprotein Profile in Patients with Nonalcoholic Steatohepatitis

34. Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH

35. Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design

36. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease

37. Therapeutic Landscape for NAFLD in 2020

38. Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels

39. The metabolic basis of nonalcoholic steatohepatitis

40. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

41. Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis

42. Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis

43. Inhibitors of Arg-Gly-Asp-Binding Integrins Reduce Development of Pancreatic Fibrosis in Mice

44. Future Treatments of NASH

45. Mo1477 WEIGHT LOSS AND CHANGE IN ALANINE AMINOTRANSFERASE (ALT) AMONG PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) RECEIVING STANDARD CARE IN REAL WORLD CLINICAL PRACTICE: TARGET-NASH

46. Clinical Profile of Adults with Nonalcoholic Steatohepatitis (NASH) With and Without Type 2 Diabetes Mellitus (T2DM)

47. Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis

48. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

49. Alarming trends in hepatic encephalopathy in the USA

50. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD